Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma

Cytopathology

Volumn 23, Issue 3, 2012, Pages 181-186

  Kumar S , K ^a   Gupta, N ^a   Rajwanshi, A ^a   Joshi, K ^a   Singh, G ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Breast carcinoma; Cell blocks; ER; Fine needle aspiration cytology; HER2; Human epidermal growth receptor 2; Oestrogen receptor; PR; Progesterone receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER TISSUE; CARCINOMA CELL; CLINICAL ARTICLE; FALSE NEGATIVE RESULT; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOCHEMISTRY; PRIORITY JOURNAL; TISSUE SECTION; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84861144843     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2011.00853.x     Document Type: Article

References (28)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Swain SM, Sorace RA, Bagley CS et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 1987;47:3889-94.
3. Rustogi A, Budrukkar A, Dinshaw K, Jalali R. Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther 2005;1:21-30.
4. Lavarino C, Corletto V, Mezzelani A et al. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer 1998;77:125-30.
5. Sauer T, Beraki E, Jebsen P et al. Assessing estrogen and progesterone receptor status in fine-needle aspirates from breast carcinomas. Results on six years of material and correlation with biochemical assay. Anal Quant Cytol Histol 1998;20:122-6.
6. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations. Cancer Cytopathol 2009;117:279-88.
7. Williams SL, Birdsong GG, Cohen C, Siddiqui MT. Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations. Int J Clin Exp Pathol 2009;2:476-80.
8. Hanley KZ, Siddiqui MT, Lawson D, Cohen C, Nassar A. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein ex-pression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis. Diagn Cytopathol 2009;37:251-7.
9. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
10. Radhika K, Prayaga AK. Estrogen and progesterone hormone receptor status in breast carcinoma: comparison of immunocytochemistry and immunohistochemistry. Ind J Cancer 2010;47:148-50.
11. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 2000;53:688-96.
12. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
13. Priti L, Lee K, Beiyun C. Correlation of HER-2 status with estrogen and progesterone reseptors and histologic features in 3655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6.
14. Ayadi L, Khabir A, Amouri H et al. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. J Surg Oncol 2008;6:112.
15. Almasri NM, Al-Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res 2005;7:R598-604.
16. Desai SB, Moonim MT, Gill AK et al. Hormone receptor status of breast cancer in India: a study of 798 tumors. Breast 2000;9:267-70.
17. Shet T, Agrawal A, Nadkarni M et al. Hormone receptors over the last 8years in a cancer referral centre in India: what was and what is? Indian J Pathol Microbiol 2009;52:171-4.
18. Chariyalertsak S, Chariyalertsak A, Ruangvejvorachai P. Immunohistochemical detection of Estrogen and Progesterone receptors in primary breast cancer. Asian Pac J Allergy Immunol 1996;16:161-6.
19. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
20. Navani S, Bhaduri AS. High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction? Indian J Pathol Microbiol 2005;48:199-201.
21. Rhodes A, Jasani B, Balaton AJ et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol 2001;115:44-58.
22. Fisher ER, Anderson S, Dean S et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005;103:164-73.
23. Wolff ASC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:1-28.
24. Fernandes RCM, Bevilacqua JLB, Soares IC et al. Coordinated expression of ER, PR and HE define different prognostic subtypes among poorly differentiated breast carcinomas. Histopathology 2009;55:346-52.
25. Matos I, Dufloth R, Alvarenga M. p63, cytokeratin 5, and pcadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;477:688-94.
26. Rakha EA, El-Sayed ME, Green AR. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
27. Lin NU, Vanderplas A, Hughes ME et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol 2009;27:15S:543.
28. Bauer KR, Brown M, Cress RD et al Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-8.